Spots Global Cancer Trial Database for prospective
Every month we try and update this database with for prospective cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure | NCT01241396 | Multiple Myelom... | Any MMY treatme... | 18 Years - 99 Years | Janssen Pharmaceutica N.V., Belgium | |
| Targeted Next Generation Sequencing for the Efficacy of Trastuzumab Neoadjuvant Chemotherapy in Breast Cancer | NCT03728829 | Observational Prospective | Trastuzumab+TP | 18 Years - 70 Years | Hebei Medical University Fourth Hospital | |
| Markers for Early Detection of Prostate Cancer | NCT00340717 | Prostate Cancer | 40 Years - 75 Years | National Institutes of Health Clinical Center (CC) | ||
| Evaluation of Maintenance With Bortezomib Plus Daratumumab (V-Dara) After Induction With Bortezomib, Melphalan, Prednisone Plus Daratumumab (VMP-Dara) in Newly Diagnosed Multiple Myeloma (MM) Patients Non-eligible for autoSCT | NCT05218603 | Multiple Myelom... Non-eligible fo... | Bortezomib Daratumumab | 18 Years - | PETHEMA Foundation | |
| Dovitinib for Imatinib/Sumitinib-failed Gastrointestinal Stromal Tumors (GIST): TKI258 | NCT01440959 | Gastrointestina... | dovitinib | 20 Years - | Asan Medical Center | |
| Cost-Effectiveness of Abdominal-based Autogenous Tissue vs Tissue Expander-Implant Reconstruction - A Feasibility Study | NCT02438449 | Breast Cancer | Breast Reconstr... | 18 Years - | McMaster University | |
| Study to Evaluate Patient Reported Outcome (PRO) and Physical Activity in Japanese Patients With HR+/HER2- Advanced Breast Cancer Treated With Palbociclib Plus Endocrine Therapy or Endocrine Monotherapy | NCT04736576 | Breast Cancer | Wearable device | 20 Years - | Pfizer | |
| Efficacy and Adverse Effects of Niraparib in Ovarian Cancer. | NCT05583799 | Ovarian Cancer | 18 Years - | First Affiliated Hospital Xi'an Jiaotong University | ||
| An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgery | NCT06117891 | Unresectable He... | Atezolizumab Bevacizumab Durvalumab Tremelimumab, | 18 Years - | Bayer | |
| Non-interventional Study of Lenalidomide in the Clinical Routine Treatment of TD Patients With IPSS Low or Int-1 MDS and Isolated Del(5q) | NCT02279654 | Myelodysplastic... | Lenalidomide | 18 Years - | Celgene | |
| Pilot Study of High Risk Lung Cancer Screening | NCT03683940 | Lung Cancer | Screening | 40 Years - 82 Years | University of Colorado, Denver | |
| Treatment of Hepatocellular Carcinoma With Radiofrequency Ablation (RFA) Associated With Postoperative TACE | NCT00730860 | Cancer of Liver | radiofrequency ... radiofrequency ... | 18 Years - 75 Years | Southwest Hospital, China | |
| Paclitaxel in Patients With Metastatic or Advanced Gastrointestinal Stromal Tumors (GIST) After Failure to Imatinib and Sunitinib | NCT02607332 | Gastrointestina... | Paclitaxel | 20 Years - | Asan Medical Center | |
| The Cohort for Patient-reported Outcomes, Imaging and Trial Inclusion in Metastatic BRAin Disease (COIMBRA) | NCT05267158 | Brain Metastase... Brain Neoplasms... | 18 Years - | UMC Utrecht | ||
| Paclitaxel in Patients With GIST With Low P-glycoprotein Expression After Failure of at Least Imatinib and Sunitinib, and Regorafenib. | NCT03944304 | Gastrointestina... | Paclitaxel | 20 Years - | Asan Medical Center | |
| A Survey Of Clinical Practice Of Adjuvant Treatment Of Breast Cancer Using Exemestane (Aromasin®) In Postmenopausal Hr+ Patients | NCT01305239 | Breast Cancer | Aromasin | 45 Years - | Pfizer | |
| Real-World Data Study to Understand Participant Treatment Outcomes for Dupuytren's Contracture | NCT05877066 | Dupuytren's Con... | 18 Years - | Endo Pharmaceuticals | ||
| The Cohort for Patient-reported Outcomes, Imaging and Trial Inclusion in Metastatic BRAin Disease (COIMBRA) | NCT05267158 | Brain Metastase... Brain Neoplasms... | 18 Years - | UMC Utrecht | ||
| A Non-Interventional Study With Aromasin® As Adjuvant Treatment Of Invasive Early Breast Cancer | NCT01121549 | Invasive Early ... | Aromasin | - | Pfizer | |
| Efficacy and Adverse Effects of Olaparib in Ovarian Cancer. | NCT04699006 | Ovarian Cancer | - | First Affiliated Hospital Xi'an Jiaotong University | ||
| Observational, Non-interventional, Non Comparative Real Life Data Collection of Depo-Eligard® 7.5 mg, 22.5 mg and 45 mg in Male Prostate Cancer Patients | NCT01793077 | Prostate Cancer | Depo-Eligard® | - | Astellas Pharma Inc | |
| Cost-Effectiveness of Abdominal-based Autogenous Tissue vs Tissue Expander-Implant Reconstruction - A Feasibility Study | NCT02438449 | Breast Cancer | Breast Reconstr... | 18 Years - | McMaster University | |
| A Non-Interventional Study With Aromasin® As Adjuvant Treatment Of Invasive Early Breast Cancer | NCT01121549 | Invasive Early ... | Aromasin | - | Pfizer | |
| Evaluation of Maintenance With Bortezomib Plus Daratumumab (V-Dara) After Induction With Bortezomib, Melphalan, Prednisone Plus Daratumumab (VMP-Dara) in Newly Diagnosed Multiple Myeloma (MM) Patients Non-eligible for autoSCT | NCT05218603 | Multiple Myelom... Non-eligible fo... | Bortezomib Daratumumab | 18 Years - | PETHEMA Foundation | |
| Efficacy and Adverse Effects of Niraparib in Ovarian Cancer. | NCT05583799 | Ovarian Cancer | 18 Years - | First Affiliated Hospital Xi'an Jiaotong University | ||
| Stage III NSCLC RWE in Chinese Patients | NCT04023812 | Carcinoma, Non-... | 18 Years - 130 Years | AstraZeneca | ||
| Imatinib Dose Escalation to 800 mg/Day in Korean Patients With Metastatic or Unresectable GIST Harboring KIT Exon 9 Mutation: KENEDI | NCT01541709 | Gastrointestina... | imatinib | 18 Years - | Asan Medical Center | |
| Thoracic Radiotherapy Plus Maintenance Durvalumab After First Line Carboplatin and Etoposide Plus Durvalumab in Extensive-stage Disease Small Cell Lung Cancer (ED-SCLC). | NCT04472949 | Small Cell Lung... Lung Cancer | Durvalumab carboplatin etoposide Thoracic radiot... | 18 Years - | Swiss Group for Clinical Cancer Research | |
| The Efficacy Of Mapping For Cognitive Prostate Biopsy | NCT05902637 | Prostate Cancer Prostate Adenoc... Prostatic Neopl... Prostate Diseas... Prostate Cancer... | Performing cogn... Performing cogn... | 40 Years - 90 Years | Marmara University | |
| A Real World Study of the Efficacy and Safety of Flumatinib Versus Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase | NCT05367765 | CML, Chronic Ph... | Flumatinib Imatinib | 18 Years - | Jiangsu Hansoh Pharmaceutical Co., Ltd. | |
| Efficacy of Propranolol Treatment to Prevent Melanoma Progression | NCT01988831 | Stages III Skin... Stages II Skin ... Stage IB Skin M... | Propranolol hyd... Placebo pill | 18 Years - | University Hospital, Geneva | |
| 5% KOH Solution vs. Placebo and Diclofenac Gel for the Treatment of Actinic Keratosis | NCT04552327 | Actinic Keratos... | Solcera Placebo Solaraze | 18 Years - | Infectopharm Arzneimittel GmbH | |
| Pilot Study of High Risk Lung Cancer Screening | NCT03683940 | Lung Cancer | Screening | 40 Years - 82 Years | University of Colorado, Denver | |
| Pilot Study of Irreversible Electroporation (IRE) to Treat Early-Stage Primary Liver Cancer (HCC) | NCT01078415 | Carcinoma, Hepa... | Ablation with t... | 18 Years - | Angiodynamics, Inc. | |
| Diabetes, Glucose Control, Glucose Lowering Medications, and Cancer Risk: A 10-year Population-based Historical Cohort | NCT02072902 | Diabetes Cancer | 21 Years - 90 Years | Sheba Medical Center | ||
| A Survey Of Clinical Practice Of Adjuvant Treatment Of Breast Cancer Using Exemestane (Aromasin®) In Postmenopausal Hr+ Patients | NCT01305239 | Breast Cancer | Aromasin | 45 Years - | Pfizer | |
| The Cohort for Patient-reported Outcomes, Imaging and Trial Inclusion in Metastatic BRAin Disease (COIMBRA) | NCT05267158 | Brain Metastase... Brain Neoplasms... | 18 Years - | UMC Utrecht | ||
| Distal Pancreatectomy, Minimally Invasive or Open, for Malignancy (DIPLOMA) | NCT04483726 | Pancreatic Duct... | minimally invas... open distal pan... | 18 Years - | University Hospital, Montpellier | |
| Huaier Granules for Prevention of Recurrence and Metastasis of Colorectal Cancer Patients Following Radical Surgery | NCT03349762 | Colorectal Canc... | 18 Years - 75 Years | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | ||
| Thoracic Radiotherapy Plus Maintenance Durvalumab After First Line Carboplatin and Etoposide Plus Durvalumab in Extensive-stage Disease Small Cell Lung Cancer (ED-SCLC). | NCT04472949 | Small Cell Lung... Lung Cancer | Durvalumab carboplatin etoposide Thoracic radiot... | 18 Years - | Swiss Group for Clinical Cancer Research | |
| Pilot Study of Irreversible Electroporation (IRE) to Treat Early-Stage Primary Liver Cancer (HCC) | NCT01078415 | Carcinoma, Hepa... | Ablation with t... | 18 Years - | Angiodynamics, Inc. | |
| Metabolic Changes in Prostate Cancer Patients With Androgen-ablation Therapy (AAT) | NCT01284608 | Prostatic Cance... | 18 Years - | AstraZeneca | ||
| Nurse-led Follow-up Care for Head and Neck Cancer Patients | NCT01167179 | Head and Neck C... | nurse-led consu... | 18 Years - | Radboud University Medical Center | |
| Prospective Collection of Samples for Urothelial Cancer of Bladder | NCT04167332 | Bladder Cancer | 18 Years - | Universitaire Ziekenhuizen KU Leuven | ||
| A Post Marketing Surveillance on Lutathera® in Patients With Somatostatin Receptor Positive Gastroenteropancreatic Neuroendocrine Tumor in Korea | NCT04946305 | Somatostatin Re... | Lutathera | 18 Years - | Novartis | |
| Paclitaxel in Patients With GIST With Low P-glycoprotein Expression After Failure of at Least Imatinib and Sunitinib, and Regorafenib. | NCT03944304 | Gastrointestina... | Paclitaxel | 20 Years - | Asan Medical Center | |
| A Post Marketing Surveillance on Lutathera® in Patients With Somatostatin Receptor Positive Gastroenteropancreatic Neuroendocrine Tumor in Korea | NCT04946305 | Somatostatin Re... | Lutathera | 18 Years - | Novartis | |
| Efficacy and Adverse Effects of Olaparib in Ovarian Cancer. | NCT04699006 | Ovarian Cancer | - | First Affiliated Hospital Xi'an Jiaotong University | ||
| Quantitative Bowel Readiness Assessment System in Predicting the Missed Detection Rate of Adenomas | NCT05145712 | Self Control Prospective Interventional | Bowel readiness | 45 Years - | Renmin Hospital of Wuhan University | |
| A Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients Using ColoPrint | NCT00903565 | Colon Cancer | 18 Years - | Agendia | ||
| Real-World Data Study to Understand Participant Treatment Outcomes for Dupuytren's Contracture | NCT05877066 | Dupuytren's Con... | 18 Years - | Endo Pharmaceuticals | ||
| A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure | NCT01241396 | Multiple Myelom... | Any MMY treatme... | 18 Years - 99 Years | Janssen Pharmaceutica N.V., Belgium | |
| Targeted Next Generation Sequencing for the Efficacy of Trastuzumab Neoadjuvant Chemotherapy in Breast Cancer | NCT03728829 | Observational Prospective | Trastuzumab+TP | 18 Years - 70 Years | Hebei Medical University Fourth Hospital |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
